Budgetary impact analysis of qPCR P210 test incorporation for the follow-up for patients with chronic myeloid leukemia in a tertiary hospital in the Federal District, Brazil

Abstract

Chronic Myeloid Leukemia (CML) is a disease that affects people aged between 40 and 60 years, mainly males. In most cases, expression of the Philadelphia chromosome occurs, which induces the production of an oncoprotein with increased tyrosine kinase activity, expected in unbridled anticipation of cells. The treatment of first choice is currently the tyrosine kinase inhibitor, Imatinib, which leads to a decrease in the number of cases of evolution from the chronic to the accelerated phase and for the proper monitoring of the molecular response of the disease, it is necessary to carry out screening tests such as qPCR, the gold standard of detection. In this work, a study was carried out to analyze the budgetary impact of incorporating the qPCR test by a tertiary hospital in the Federal District to improve CML screening to promote continuity in patient care. A budget impact analysis (BIA) was performed to evaluate the incorporation of the qPCR BCR-ABL p210 test for monitoring chronic myeloid leukemia in patients in the Federal District, compared to carrying out the tests through a contract with a third-party laboratory. According to the AIO, the contract had a smaller budgetary impact than the incorporation of qPCR test by the hospital. For instance, it is better to keep the current contract.